

Treasury Board Secretariat

Assistant Deputy Minister's Office
Employee Relations and Negotiations
Division

Centre for Public Sector Labour
Relations and Compensation

OPS Strategic Labour Relations and
Compensation Practice Group

315 Front Street West
6th Floor
Toronto, ON M7A 0B8

Secrétariat du conseil du trésor

Bureau du sous-ministre adjoint
Division des relations avec le personnel et des
négociations

Centre pour les relations de travail et
la rémunération dans le secteur public
Groupe des pratiques pour les relations de
travail stratégiques et la rémunération dans la
FPO

315, rue Front Ouest
6^{ème} étage
Toronto, ON M7A 0B8



October 1, 2026

Mr. Dave Bulmer
President
AMAPCEO
1 Dundas Street West, Suite 2310
PO Box 72
Toronto, ON M5G 1Z3

Mr. Chris Eckhert
CERC/MERC Chair
OPSEU/SEFPO
100 Lesmill Road
North York, ON M3B 3P8

Dear Mr. Bulmer and Mr. Eckhert:

Thank you for your joint correspondence of August 12, 2026, regarding coverage for GLP-1 medications, including semaglutide products, under the OPS group insurance benefit plans.

We appreciate the concerns raised by AMAPCEO and OPSEU/SEFPO regarding access to emerging therapies and generic alternatives. The Employer remains committed to providing a comprehensive and sustainable benefits program in accordance with the applicable collective agreements and group insurance plans.

Prescription drug coverage is governed by the negotiated plan design for each bargaining unit, including prior authorization, generic substitution and other drug management provisions. Because bargaining units have separate collective agreements, plan designs and insurance carriers, coverage, adjudication and formulary outcomes may differ across groups.

Under the existing plan terms, Ozempic is eligible for coverage for type 2 diabetes, subject to prior authorization and enhanced generic substitution provisions. It is not covered for other indications, including weight management, whether prescribed as Ozempic or as a Health Canada-approved generic equivalent.

The introduction of a generic equivalent does not change coverage eligibility. Any approved generic semaglutide product, and future generic versions of GLP-1 medications, will be administered under the same applicable plan provisions, including prior authorization, generic substitution and drug management requirements.

Any changes to plan terms and design to expand coverage are best addressed through the collective bargaining process.

Thank you for sharing your views and for your continued advocacy on behalf of represented employees. We value our ongoing dialogue with bargaining agents on employee benefits matters.

Sincerely,

Original Signed By

Steven Mackay
Assistant Deputy Minister
Employee Relations and Negotiations Division
Centre for Public Sector Labour Relations and Compensation
Treasury Board Secretariat

c: Matt Siple, Chief Negotiations Officer, Centre for Public Sector Labour Relations and Compensation, Treasury Board Secretariat

Laura Settino, (A) Assistant Deputy Minister, Total Rewards and Classification Division, Centre for Public Sector Labour Relations and Compensation, Treasury Board Secretariat